NAGE Niagen Bioscience Inc
USHealthcareAs of 2026-10-08
Why NAGE matters now
Niagen Bioscience Inc (NAGE) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.66 with -2.21% on the session and $211.9M in market capitalization; recent performance reads 1-month -4.63% and YTD -44.97%.
The latest financial table shown here is Q1 2026, with revenue of $31.5M, net income of $6.3M, and EPS of $0.07. Investors can compare that operating picture with valuation signals such as P/E 20.59 and FCF yield 1.5%.
The latest indexable market news headline is "Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $10.50; recent insider activity includes Fried Robert N filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
20.59
PEG
0.20
P/B
3.40
P/S
2.14
EV/EBITDA
10.04
DCF Value
$-1.52
FCF Yield
1.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
64.3%
Operating Margin
8.5%
Net Margin
14.3%
ROE
25.4%
ROA
16.3%
ROIC
11.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $31.5M | $6.3M | $0.07 |
| Q4 2025 | $33.8M | $4.1M | $0.05 |
| FY 2025 | $129.4M | $17.4M | $0.20 |
| Q3 2025 | $34.0M | $4.6M | $0.05 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$10.50
Target (Median)
$10.50
Target Range
$10.00 - $11.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.06
Niagen Bioscience Inc operates as a biotechnology enterprise with a core focus on promoting healthy aging. This company is also renowned for its pioneering research into nicotinamide adenine dinucleotide.